Testsúlykontroll kezelések

Weight management kezelések Európában

Excess weight and obesity represent one of the most significant public health challenges across the European Union. According to the World Health Organization, more than half of adults in the WHO European Region are overweight, and approximately 23% live with obesity. The health consequences extend well beyond aesthetics: obesity is a chronic condition associated with type 2 diabetes, cardiovascular disease, hypertension, sleep apnoea, and certain cancers.

For many people, lifestyle interventions — dietary changes and increased physical activity — are the foundation of weight management. However, clinical evidence consistently shows that for individuals with a BMI of 30 or above, or 27 or above with weight-related health conditions, prescription medications can provide meaningful additional benefit when used alongside lifestyle modifications.

The past decade has seen a significant advancement in the pharmacological options available for weight management in Europe. The approval of GLP-1 receptor agonists by the European Medicines Agency (EMA) has given doctors access to medications with demonstrated efficacy: clinical trials published in the New England Journal of Medicine show that semaglutide (the active ingredient in both Ozempic and Wegovy) produced an average weight reduction of approximately 15% of body weight over 68 weeks in adults with obesity. This represents a step-change compared to older weight management medications.

It is important to understand that prescription weight management medications are not a substitute for lifestyle changes, and they are not appropriate for everyone. All prescribing decisions must be made by a qualified, independent doctor based on a thorough assessment of each individual’s clinical circumstances.

Elérhető kezelések

The following prescription medications are available for weight management through EU-registered doctors. This comparison is provided for informational purposes only. A doctor will assess which medication, if any, is appropriate for your individual situation.

Key distinctions:

• Ozempic vs Wegovy: Both contain semaglutide, a GLP-1 receptor agonist. Ozempic carries EMA approval for type 2 diabetes management; Wegovy is the formulation approved specifically for chronic weight management at a higher maximum dose. Clinical data indicates that the higher semaglutide dose in Wegovy produces greater average weight loss.
• Saxenda: Contains liraglutide, a different GLP-1 receptor agonist requiring daily rather than weekly injections. Clinical head-to-head evidence suggests semaglutide achieves greater mean weight reduction than liraglutide over comparable treatment periods.
• Starting price: Prices vary by country, pharmacy, and dosage. Use the links above to see indicative starting prices for each medication through Prescrivia’s platform.

Hogyan szerezhető be a kezelések online

A Prescrivia technológiai közvetítőként működik: nem írunk fel gyógyszereket, nem alkalmazunk orvosokat és nem értékesítünk gyógyszereket. Platformunk pácienseket kapcsol össze független, EU-ban regisztrált orvosokkal, akik bizalmas online egészségügyi felméréseket végezhetnek.

A folyamat a következő:

1. Töltse ki az egészségügyi kérdőívet — Answer a structured set of medical questions covering your health history, current medications, BMI, and weight management goals. The assessment is designed to give the reviewing doctor a thorough clinical picture.

2. Independent doctor review — An independent EU-registered doctor reviews your assessment. If a prescription medication is clinically appropriate for you, the doctor may issue a prescription. If it is not appropriate — due to contraindications, insufficient clinical indication, or other factors — the doctor will explain the reasoning.

3. Recept és teljesítés — If a prescription is issued, it is passed to a licensed EU pharmacy partner. The pharmacy dispenses the medication and arranges delivery directly to your address.

Fontos: A Prescrivia nem garantálja a recept kiállítását. Minden felírási döntést független, képzett orvosok hoznak az Ön egyéni klinikai körülményei alapján. All medications are prescription-only medicines (POMs) in EU member states and require a valid prescription from a licensed doctor.

Összehasonlításunk

Note: For patients with complex medical histories, multiple comorbidities, or conditions requiring close clinical monitoring, an in-person consultation with a GP or specialist may be more appropriate. Prescrivia’s platform is designed for adults who meet the clinical criteria for prescription weight management medications and whose health profile is suitable for remote assessment.

Források

Az oldalon található orvosi információk az alábbi forrásokon alapulnak:

• European Medicines Agency (EMA). Wegovy (semaglutide) — Summary of Product Characteristics. Available at: ema.europa.eu
• European Medicines Agency (EMA). Saxenda (liraglutide) — Summary of Product Characteristics. Available at: ema.europa.eu
• World Health Organization (WHO). Obesity and overweight in the WHO European Region — Fact sheet. euro.who.int
• Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384:989-1002.

Ez a tartalom rendszeresen felülvizsgálatra kerül a frissített klinikai irányelvek tükrözése érdekében. Kizárólag tájékoztató jelleggel készült, és nem minősül orvosi tanácsadásnak. Mindig konzultáljon képzett egészségügyi szakemberrel az Ön egyéni egészségügyi körülményeire vonatkozó tanácsért.